Tempus AI expanded its strategic collaboration with Bristol Myers Squibb to improve clinical development success rates. The partnership leverages Tempus’ AI platform and multimodal real-world data to optimize the design of five initial clinical trials.
The initiative utilizes the Lens analytical platform to evaluate complex patient data and validate control group assumptions. This technology identifies specific patient segments most likely to respond to investigational therapies.
Initial efforts focus on solid tumor oncology assets for lung, colon, and prostate cancers. The collaboration also extends into neuroscience to advance drug development for Alzheimer’s Disease.